From the updated landscape of the emerging biologics for IBDs treatment to the new delivery systems

J Yang, D Li, M Zhang, G Lin, S Hu, H Xu - Journal of Controlled Release, 2023 - Elsevier
Inflammatory bowel diseases (IBDs) treatments have shifted from small-molecular
therapeutics to the oncoming biologics. The first-line biologics against the moderate-to …
被引用次数：11 相关文章

From the updated landscape of the emerging biologics for IBDs treatment to the new delivery systems

J Yang, D Li, M Zhang, G Lin, S Hu… - Journal of controlled … - pubmed.ncbi.nlm.nih.gov
Inflammatory bowel diseases (IBDs) treatments have shifted from small-molecular
therapeutics to the oncoming biologics. The first-line biologics against the moderate-to …

From the updated landscape of the emerging biologics for IBDs treatment to the new delivery systems

J Yang, D Li, M Zhang, G Lin, S Hu… - Journal of Ophthalmology …, 2023 - journals.lww.com
Inflammatory bowel diseases (IBDs) treatments have shifted from small-molecular
therapeutics to the oncoming biologics. The first-line biologics against the moderate-to …